Back to top
more

Epizyme, Inc. (EPZM)

(Delayed Data from NSDQ)

$12.10 USD

12.10
622,659

+0.19 (1.60%)

Updated May 3, 2019 04:00 PM ET

After-Market: $12.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of -15.69% and 51.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.

Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates

by Zacks Equity Research

It was a low-key week for the biotech sector with updates from just a few small biotech companies.

Epizyme (EPZM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Epizyme (EPZM) closed at $21.78 in the latest trading session, marking a -0.5% move from the prior day.

Epizyme (EPZM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Epizyme (EPZM) closed at $20.93, marking a -1.83% move from the previous day.

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

by Zacks Equity Research

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

Are You Looking for a Top Momentum Pick? Why Epizyme (EPZM) is a Great Choice

by Zacks Equity Research

Does Epizyme (EPZM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma

by Zacks Equity Research

Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.

Axsome (AXSM) Completes Patient Randomization in TRD Study

by Zacks Equity Research

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

Is Epizyme (EPZM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (EPZM) Outperforming Other Medical Stocks This Year?

Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

by Zacks Equity Research

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

Is the Options Market Predicting a Spike in Epizyme (EPZM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.

Seattle Genetics Up More Than 40% in the Past Year: Here's Why

by Zacks Equity Research

Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

by Zacks Equity Research

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

Applied Therapeutics Up on Positive Galactosemia Study Data

by Zacks Equity Research

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

What Makes Epizyme (EPZM) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Epizyme (EPZM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Blueprint Medicines Initiates Dosing in Liver Cancer Study

by Zacks Equity Research

Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.

aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

by Zacks Equity Research

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

Epizyme (EPZM) Shares Soar on Lead Candidate's Progress

by Zacks Equity Research

Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies

Will Epizyme Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Epizyme.